AXON ENTERPRISE, INC. (AXON) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
AXON currently has 76.9M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 1.82% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Dec 10, 2025 |
8-K filing: Axon Enterprise, Inc. entered into exchange agreements with certain holders to exchange approximately $177.9 million aggregate principal amount of Notes for cash and approximately 468,000 shares of its common stock, expected to close on or about December 16, 2025. |
77M | 0 |
| May 07, 2025 |
10-Q filing | 76.9M shares outstanding |
77M | 0 |
| Mar 07, 2025 |
8-K filing: Axon Enterprise, Inc. entered into exchange agreements with certain holders of its 0.50% convertible senior notes due 2027 to exchange approximately $407.5 million aggregate principal amount of the Notes for cash and approximately 1.0 million shares of common stock, expected to close on or about March 13, 2025. |
76M | 0 |
| Feb 28, 2025 |
10-K filing | 75.7M shares outstanding |
76M | 0 |
| Nov 08, 2024 |
10-Q filing | 75.7M shares outstanding |
76M | 0 |
| Aug 07, 2024 |
10-Q filing | 75.5M shares outstanding |
76M | 0 |
| May 07, 2024 |
10-Q filing | 75.4M shares outstanding |
75M | 0 |
| Feb 27, 2024 |
10-K filing | 74.2M shares outstanding |
74M | 0 |
| Nov 07, 2023 |
10-Q filing | 74.8M shares outstanding |
75M | 0 |
| Aug 08, 2023 |
10-Q filing | 74.2M shares outstanding |
74M | 0 |
| May 09, 2023 |
10-Q filing | 73.9M shares outstanding |
74M | 0 |
| Feb 28, 2023 |
10-K filing | 71.1M shares outstanding |
71M | 0 |
| Dec 09, 2022 |
8-K filing: Axon Enterprise, Inc. issued $690 million of 0.50% Convertible Senior Notes due 2027 and entered into convertible note hedge and warrant transactions, potentially diluting common stock upon conversion or warrant exercise. ($124.3M proceeds) |
71M | 0 |
| Nov 09, 2022 |
10-Q filing | 71.1M shares outstanding |
71M | 0 |
| Aug 09, 2022 |
10-Q filing | 71.0M shares outstanding |
71M | 0 |
| May 10, 2022 |
10-Q filing | 71.0M shares outstanding |
71M | 0 |
| Feb 25, 2022 |
10-K filing | 66.2M shares outstanding |
66M | 0 |
| Nov 15, 2021 |
10-Q filing | 66.2M shares outstanding |
66M | 0 |
| Aug 10, 2021 |
8-K filing: Axon Enterprise, Inc. entered into a distribution agreement with J.P. Morgan Securities LLC, allowing the Company to sell up to 3,000,000 shares of its common stock from time to time through the Agent. |
65M | 0 |
| Aug 06, 2021 |
10-Q filing | 65.2M shares outstanding |
65M | 0 |
| May 07, 2021 |
10-Q filing | 64.0M shares outstanding |
64M | 0 |
| Apr 08, 2021 |
8-K filing: Axon Enterprise, Inc. entered into a Share Purchase Agreement with Cellebrite DI Ltd. to purchase 9,000,000 shares of Cellebrite's common stock at $10.00 per share for an aggregate purchase price of $90,000,000. ($90.0M proceeds) |
62M | 0 |
| Feb 26, 2021 |
10-K filing | 61.8M shares outstanding |
62M | 0 |
| Nov 06, 2020 |
10-Q filing | 63.5M shares outstanding |
63M | 0 |
| Aug 07, 2020 |
10-Q filing | 60.3M shares outstanding |
60M | 0 |
| Jun 18, 2020 |
8-K filing: Axon Enterprise, Inc. entered into an underwriting agreement to issue and sell 3,000,000 shares of common stock in an underwritten public offering, with the underwriters exercising their option to purchase an additional 450,000 shares, resulting in estimated net proceeds of approximately $306.7 million. ($306.7M proceeds) |
60M | 0 |
| May 08, 2020 |
10-Q filing | 59.6M shares outstanding |
60M | 0 |
| Feb 28, 2020 |
10-K filing | 59.2M shares outstanding |
59M | 0 |